This innovative therapy involves autologous dendritic cell preparation targeting prostatic acid phosphatase (PAP) and is utilized in managing patients with castration-resistant prostate cancer, showing significant improvements in overall survival outcomes.797 Tumor-associated antigens (TAAs), which are non-mutated self-antigens, have exhibited limited clinical efficacy and potential adverse effects like central tolerance and excessive autoimmune toxicity. Here, ACP3 is linked to prostate carcinoma.